Header

UZH-Logo

Maintenance Infos

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study


van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C; et al; Stupp, Roger (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, 390(10103):1645-1653.

Statistics

Citations

Dimensions.ai Metrics
27 citations in Web of Science®
21 citations in Scopus®
23 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

41 downloads since deposited on 27 Oct 2017
41 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:8 August 2017
Deposited On:27 Oct 2017 07:01
Last Modified:23 Sep 2018 06:10
Publisher:Elsevier
ISSN:0140-6736
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/S0140-6736(17)31442-3
PubMed ID:28801186

Download

Download PDF  'Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 325kB
View at publisher